���构特征与受体作用机制 — Research Overview

By Editorial Desk · published 2025-09-13 · last reviewed 2025-11-02 · Info

The short version of 长效肽设计 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Background and Drug Class

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Semaglutide at a glance

Mechanism and Pharmacological Class

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Related pages on this site

• Balanced dataset
• Standard notes
• Gradual workbook
• Balanced update
• Tracked reference
• Simple guide
• Connected reference
• Quality playbook

Background and Mechanism of Action

Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.

Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.

Semaglutide Structure and Receptor Mechanism

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Background and Molecular Design

Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.

The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.

Supporting material

Most of the remaining nonvisceral fat is found just below the skin in a region called the hypodermis. This subcutaneous fat is not related to many of the classic obesity-related pathologies, such as heart disease, cancer, and stroke, and some evidence even suggests it might be protective. The typically female (or gynecoid) pattern of body fat distribution around the hips, thighs, and buttocks is subcutaneous fat, and therefore poses less of a health risk compared to visceral fat. Like all other fat organs, subcutaneous fat is an active part of the endocrine system, secreting the hormones leptin and resistin. The relationship between the subcutaneous adipose layer and total body fat in a person is often modelled by using regression equations. The most popular of these equations was formed by Durnin and Wormersley, who rigorously tested many types of skinfold, and, as a result, created two formulae to calculate the body density of both men and women. These equations present an inverse correlation between skinfolds and body density—as the sum of skinfolds increases, the body density decreases. Factors such as sex, age, population size or other variables may make the equations invalid and unusable, and, as of 2012, Durnin and Wormersley's equations remain only estimates of a person's true level of fatness. New formulae are still being created.

=== High Performance Liquid Chromatography === High Performance Liquid Chromatography (HPLC) in the field of microfluidics comes in two different forms. Early designs included running liquid through the HPLC column then transferring the eluted liquid to microfluidic chips and attaching HPLC columns to the microfluidic chip directly. The early methods had the advantage of easier detection from certain machines like those that measure fluorescence. HPLC columns have been integrated into microfluidic chips. The main advantage of integrating HPLC columns into microfluidic devices is the smaller form factor that can be achieved, which allows for additional features to be combined within one microfluidic chip. Integrated chips can also be fabricated from multiple different materials, including glass and polyimide which are quite different from the standard material of PDMS used in many different droplet-based microfluidic devices. This is an important feature because different applications of HPLC microfluidic chips may call for different pressures. PDMS fails in comparison for high-pressure uses compared to glass and polyimide. High versatility of HPLC integration ensures robustness by avoiding connections and fittings between the column and chip. The ability to build off said designs in the future allows the field of microfluidics to continue expanding its potential applications. The potential applications surrounding integrated HPLC columns within microfluidic devices have proven expansive over the last 10–15 years.

Essential amino acid deficiency should be distinguished from protein-energy malnutrition, which can manifest as marasmus or kwashiorkor. Kwashiorkor was once attributed to pure protein deficiency in individuals who were consuming enough calories ("sugar baby syndrome"). However, this theory has been challenged by the finding that there is no difference in the diets of children developing marasmus as opposed to kwashiorkor. Still, for instance in Dietary Reference Intakes (DRI) maintained by the USDA, lack of one or more of the essential amino acids is described as protein-energy malnutrition.

=== Controversy of term === There is debate on whether the term "cyber warfare" is accurate. In 2012, Eugene Kaspersky, founder of Kaspersky Lab, concluded that "cyberterrorism" is a more accurate term than "cyberwar." He states that "with today's attacks, you are clueless about who did it or when they will strike again. It's not cyber-war, but cyberterrorism." Howard Schmidt, former Cyber Security Coordinator in the Obama administration, said that "there is no cyberwar... I think that is a terrible metaphor and I think that is a terrible concept. There are no winners in that environment." Some experts take issue with the possible consequences linked to the warfare goal. In 2011, Ron Deibert, of Canada's Citizen Lab, warned of a "militarization of cyberspace", as militaristic responses may not be appropriate. However, to date, even serious cyber-attacks that have disrupted large parts of a nation's electrical grid (230,000 customers, Ukraine, 2015) or affected access to medical care, thus endangering life (UK National Health Service, WannaCry, 2017) have not led to military action. In 2017, Oxford academic Lucas Kello proposed a new term, "Unpeace", to denote highly damaging cyber actions whose non-violent effects do not rise to the level of traditional war. Such actions are neither warlike nor peace-like. Although they are non-violent, and thus not acts of war, their damaging effects on the economy and society may be greater than those of some armed attacks.

Little gastrin I also known as '''gastrin-17''' or ''G-17''', is a 17-amino acid Peptide hormone and the most abundant form of gastrin found in healthy individuals.It is produced primarily by G-cells in the Gastric antrum and plays a key role in regulating gastric acid secretion and digestion. The existence of gastrin was first proposed by British physiologist John Sydney Edkins in 1905, though its structure was not fully worked out until the 1960s. Little gastrin I is synthesized from a larger precursor protein called preprogastrin, which undergoes several processing steps before producing the mature hormone. It stimulates parietal cells in the stomach to secrete hydrochloric acid and is involved in gastric motility and the release of pepsin and intrinsic factor. Its release is triggered by food intake and inhibited by low stomach pH, forming a negative feedback loop. Abnormally high levels of gastrin, known as hypergastrinemia, are associated with conditions such as atrophic gastritis, pernicious anemia, and gastric cancer.

Sources: en.wikipedia.org

Supporting material

Nuclear magnetic resonance was first described and measured in molecular beams by Isidor Rabi in 1938, by extending the Stern–Gerlach experiment, and in 1944, Rabi was awarded the Nobel Prize in Physics for this work. In 1946, Felix Bloch and Edward Mills Purcell expanded the technique for use on liquids and solids, for which they shared the Nobel Prize in Physics in 1952. Russell H. Varian filed the "Method and means for correlating nuclear properties of atoms and magnetic fields", U.S. patent 2,561,490 on October 21, 1948 and was accepted on July 24, 1951. Varian Associates developed the first NMR unit called NMR HR-30 in 1952. Purcell had worked on the development of radar during World War II at the Massachusetts Institute of Technology's Radiation Laboratory. His work during that project on the production and detection of radio frequency power and on the absorption of such RF power by matter laid the foundation for his discovery of NMR in bulk matter. Rabi, Bloch, and Purcell observed that magnetic nuclei, like 1H and 31P, could absorb RF energy when placed in a magnetic field and when the RF was of a frequency specific to the identity of the nuclei. When this absorption occurs, the nucleus is described as being in resonance. Different atomic nuclei within a molecule resonate at different (radio) frequencies in the same applied static magnetic field, due to various local magnetic fields.

=== Medical guidelines and recommendations === In 2015, the scientific advisory panel of U.S. Department of Health and Human Services and U.S. Department of Agriculture for the 2015 iteration of the Dietary Guidelines for Americans dropped the previously recommended limit of consumption of dietary cholesterol to 300 mg per day with a new recommendation to "eat as little dietary cholesterol as possible", thereby acknowledging an association between a diet low in cholesterol and reduced risk of cardiovascular disease. A 2013 report by the American Heart Association and the American College of Cardiology recommended focusing on healthy dietary patterns rather than specific cholesterol limits, as they are hard for clinicians and consumers to implement. They recommend the DASH and Mediterranean diet, both of which are low in cholesterol. A 2017 review by the American Heart Association recommends switching saturated fats for polyunsaturated fats to reduce cardiovascular disease risk. Some supplemental guidelines have recommended doses of phytosterols in the order of 1.6‍–‍3.0 grams per day (Health Canada, EFSA, ATP III, FDA). A meta-analysis demonstrated a 12% reduction in LDL-cholesterol at a mean dose of 2.1 grams per day. The benefits of a diet supplemented with phytosterols have also been questioned.

During the 2024 presidential election, Moore was a member of the Biden-Harris Campaign National Advisory Board and campaigned for President Joe Biden in Wisconsin and Georgia. He also defended Biden from calls to drop out of the presidential election amid the first 2024 presidential debate, highlighting Biden's accomplishments in office while conceding that the debate was a "rough night" for the president. After Biden withdrew from the race on July 21, 2024, Moore endorsed and campaigned for Vice President Kamala Harris. During the 2024 United States Senate election in Maryland, Moore endorsed Prince George's County Executive Angela Alsobrooks in the Democratic primary over U.S. representative David Trone. He played an active role in campaigning against Republican nominee and former governor Larry Hogan in the general election, with several of his top advisors leaving their positions in the Moore administration to form a political action committee called Unity First PAC to support Alsobrooks and other Democratic nominees downballot.

== Operations == EFLM has an Executive Board and a range of committees for: science, education and training, quality and regulations, communication and professional representation. Each committee has working groups with a Chair and three full members, there is also a Young Scientist member and they may also have corresponding members, but only one member form each country is permitted. The Science Committee develops collaborative science in Laboratory Medicine between member organisations or individuals and guidelines to set standards of practice to assist member societies in providing quality patient care. The output of the scientific working groups is scientific papers and presentations which contribute to the science of laboratory medicine internationally; a list of publications can be found on the EFLM web-site (link below). Typically publications are peer-reviewed and published in the journal Clinical Chemistry and Laboratory Medicine. The Working Groups are overseen by the Chair of the Science Committee and their activities reviewed annually; scientific and clinically relevant output determine whether they continue. The Education and Training Committee runs educational activities particularly for trainees and those required to develop new skills as well as running scientific and clinical conferences, webinars, etc. The major Congress is Euromedlab held in conjunction with the IFCC, meetings are selected from bids by member societies at the annual General Meeting.

Dextrorphan (DXO) is a psychoactive drug of the morphinan class which acts as an antitussive or cough suppressant and in high doses a dissociative hallucinogen. It is the dextrorotatory enantiomer of racemorphan; the levorotatory enantiomer is levorphanol. Dextrorphan is produced by O-demethylation of dextromethorphan by CYP2D6. Dextrorphan is an NMDA antagonist and contributes to the psychoactive effects of dextromethorphan.

Sources: en.wikipedia.org

Frequently asked questions